Investigational drug · Phase 2
LB-100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myelodysplastic Syndromes.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 8, 2019 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "LB-100"
First trial start
2019
Apr 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LB-100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
Approved drugs for the same conditions: Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "LB-100" as an intervention, largest first.
- Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue SarcomasPivotal-lookingActive, not recruiting
Grupo Espanol de Investigacion en SarcomasAcademic, hospital or other
NCT05809830 · 152 participants (planned) · Start May 29, 2023 · Primary completion Jun 20, 2025
Drug: LB-100 plus Doxorrubicin; Doxorubicin · For: Advanced Soft-tissue Sarcoma
Sites: Barcelona, Spain; Madrid, Spain; Murcia, Spain · 6 sites in all
- A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)Recruiting
Lixte Biotechnology Holdings, Inc.Industry
NCT03886662 · 47 participants (planned) · Start Apr 2019 · Primary completion May 2021
Drug: LB-100 · For: Myelodysplastic Syndromes
Sites: Tampa, Florida
- LB-100 (PP2A Inhibitor) and Atezolizumab (PD-L1 Inhibitor) in Metastatic Colorectal Cancer PatientsRecruiting
The Netherlands Cancer InstituteAcademic, hospital or other
NCT06012734 · 37 participants (planned) · Start Jun 18, 2024 · Primary completion Jul 2028
Drug: LB-100; Atezolizumab · For: Metastatic Microsatellite-stable Colorectal Cancer
Sites: Amsterdam, Netherlands
Lixte Biotechnology Holdings, Inc.Industry
NCT01837667 · 29 participants · Start Feb 2013 · Primary completion Sep 2016
Drug: LB-100 for Injection; Docetaxel · For: Tumors; Neoplasms; Cancer
Sites: Duarte, California; Rochester, Minnesota; Las Vegas, Nevada · 5 sites in all
- Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100Recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06065462 · 21 participants (planned) · Start Nov 10, 2023 · Primary completion Oct 1, 2027
Drug: Dostarlimab; LB-100 · For: Ovarian Clear Cell Carcinoma
Sites: Houston, Texas
National Cancer Institute (NCI)NIH
NCT03027388 · 7 participants · Start Jan 9, 2019 · Primary completion Aug 15, 2022
Drug: LB-100 · For: Astrocytoma, Grades II, III and IV; Glioblastoma Multiforme; Giant Cell Glioblastoma and 2 more
Sites: Bethesda, Maryland
- LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruiting
City of Hope Medical CenterAcademic, hospital or other
NCT04560972 · 3 participants · Start May 28, 2021 · Primary completion Jan 27, 2027
Drug: Atezolizumab; Carboplatin and 2 more · For: Extensive Stage Lung Small Cell Carcinoma
Sites: Duarte, California
Newest research
PubMed records naming it or its code names, newest first.
- Development of glutamatergic antipsychotics requires efficient synaptic glutamatergic transmission while preventing NMDA receptor down-regulation and overactivation of extrasynaptic transmission.
Okubo R, Oka T, Motomura E, et al. · Br J Pharmacol 2026
- PP2Acα regulates the Hippo-YAP signaling axis to promote cardiac regeneration and alleviate myocardial infarction.
Wang A, Qin B, Lee MCJ, et al. · J Mol Cell Cardiol 2026
- Green additives effectiveness in water-based drilling mudߒperformance: A study of pistachio shell powder, magnesium oxide, and carbon black particles.
Kudapa VK, Kosasih W, Saravanan AR, et al. · PLoS One 2026
- Polystyrene nanoplastics drive neuronal senescence via PP2A-B56γ-targeted p-Ebp1Ser335 dephosphorylation-mediated ribosome biogenesis dysfunction.
Gao YL, Wang MZ, Wang LL, et al. · Free Radic Biol Med 2026
- Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models.
Ho WS, Mondal I, Liu J, et al. · J Clin Invest 2026
- Lactic acid bacterial strains isolated from Attiéké (semolina cassava): bio-tools for combating emergent pathogens in the context of climate change.
Coulibaly WH, Tohoyessou YMG, Ohin ABM, et al. · Front Microbiol 2026
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.